Bachem Holding مُضاعَف الربحِية 2024

ماذا تفعل Bachem Holding؟

The Bachem Holding AG is a leading provider of peptides and biochemical agents for the pharmaceutical and biotechnological industry. The company was founded in 1971 in Bubendorf, Switzerland, and has been listed on the Swiss stock exchange since 1998. The company's history began with the founding of Bachem Chemie GmbH by Peter Grogg, a former chemical engineer at Ciba-Geigy. Grogg started the company with a focus on peptide synthesis, an area that was still in its infancy at the time. Over time, Bachem expanded its core business by entering into other areas such as peptide formulation, plant extract manufacturing, and nucleotide synthesis. Today, the company has around 1,400 employees worldwide and operates production and research facilities in Europe, North America, and Asia. Bachem is considered one of the largest peptide manufacturers globally and supplies customers in over 100 countries. The business model of Bachem Holding AG is heavily focused on research and development (R&D). The company invests approximately 15% of its revenue annually in R&D to maintain and expand its leading position in peptide chemistry and biochemical agents. These investments have allowed Bachem to offer a wide range of products and services that meet various customer requirements. The company operates several business segments, including peptides and biochemicals, pharmaceutical contract manufacturing and GMP manufacturing, generic drugs, research services, and products for the diagnostics market. The peptides and biochemicals segment is the core of the company and includes a wide range of peptides, amino acids, peptide libraries, peptide-drug conjugates, synthetic proteins, and bioactive peptides. Bachem also manufactures synthetic peptide kits and customized peptides for research and development. The company is also active in pharmaceutical contract manufacturing, offering customized manufacturing services for bioactive peptides, synthetic drugs, oligonucleotides, and drug-drug conjugates. Customers can benefit from synthesis development to commercial production of active substances. Bachem has also positioned itself in the generic drug market, offering a wide range of peptide-based generics such as buserelin, leuprorelin, and triptorelin. The generic drugs segment was expanded in 2015 through the acquisition of the American biotechnology company American Peptide Company. In addition to manufacturing peptides and biochemical agents, Bachem also provides research services, including peptide synthesis, peptide conjugation with drugs, analysis of protein-protein interactions, and identification of peptide libraries. The company is also active in the diagnostics market, offering a wide range of peptides and antibodies for use in diagnostic products for research and clinical applications. In summary, the Bachem Holding AG is a leading provider of peptides and biochemical agents for the pharmaceutical and biotechnological industry. The company heavily invests in research and development and offers a wide range of products and services to meet various customer requirements. Bachem Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.